# AstraZeneca

临床管线 — 加速试验.

Source: https://cn.bioecon.ru/companies/astrazeneca/
Updated: 2026-07-02

- 国家: United Kingdom

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 与石药集团合作，首付款及里程碑付款$47亿 | https://www.proactiveinvestors.co.uk/companies/news/1087094/astrazeneca-lifts-earnings-as-pipeline-delivery-and-global-expansion-underpin-growth-1087094.html |
| 产能 | Macclesfield基地：7200万盒药品；利物浦基地：年产2000万剂疫苗 | https://careers.astrazeneca.com/united-kingdom |
| 监管批准 | FY2025在主要市场获43项监管批准；2026年上半年获8项首次批准；自2025年第四季度业绩以来在主要地区获30项批准 | https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2025/pdf/AstraZeneca_AR_2025_CEO_Review.pdf, https://www.proactiveinvestors.co.uk/companies/news/1087094/astrazeneca-lifts-earnings-as-pipeline-delivery-and-global-expansion-underpin-growth-1087094.html |
| 生产基地 | Macclesfield（药品生产）、Speke（生物制品）及利物浦（疫苗） | https://careers.astrazeneca.com/united-kingdom |
| 员工人数 | 英国约10,000名员工 | https://careers.astrazeneca.com/united-kingdom, https://www.astrazeneca.co.uk/content/dam/intelligentcontent/unbranded/astrazeneca/uk/en/pdf/AstraZeneca-UK-Purpose-Led-Partnerships-Prospectus-2025.pdf |
| 营收 | FY2025总收入$587亿；2026年上半年$306.72亿 | https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2025/pdf/AstraZeneca_AR_2025_CEO_Review.pdf, https://www.astrazeneca.com/media-centre/press-releases/2026/h1-and-q2-2026-results.html, https://www.proactiveinvestors.co.uk/companies/news/1087094/astrazeneca-lifts-earnings-as-pipeline-delivery-and-global-expansion-underpin-growth-1087094.html |

独立来源: proactiveinvestors.co.uk

## 技术

- [企业生物技术加速器（JLABS、拜耳CoLaborator）](https://cn.bioecon.ru/technology/corporate-biotech-accelerators/)
- [抗体偶联药物（ADC）](https://cn.bioecon.ru/technology/antibody-drug-conjugates-adcs/)